Search Results - "Silar, Jiri"

Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma by Hájek, Roman, Minařík, Jiří, Straub, Jan, Pour, Luděk, Jungova, Alexandra, Berdeja, Jesus G, Boccadoro, Mario, Brozova, Lucie, Spencer, Andrew, Rhee, Frits van, Vela-Ojeda, Jorge, Thompson, Michael A, Abonour, Rafat, Chari, Ajai, Cook, Gordon, Costello, Caitlin L, Davies, Faith E, Hungria, Vania Tm, Lee, Hans C, Leleu, Xavier, Puig, Noemi, Rifkin, Robert M, Terpos, Evangelos, Usmani, Saad Z, Weisel, Katja C, Zonder, Jeffrey A, Bařinová, Magda, Kuhn, Matyáš, Šilar, Jiří, Čápková, Lenka, Galvez, Kenny, Lu, Jin, Elliott, Jennifer, Stull, Dawn Marie, Ren, Kaili, Maisnar, Vladimír

“…To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice…”
Get full text

Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice by Buchler, Tomas, Kiss, Igor, Hornova, Jana, Fiala, Ondrej, Wiesnerova, Marketa, Svoboda, Michal, Silar, Jiri, Kopeckova, Katerina, Poprach, Alexandr, Finek, Jindrich, Petruzelka, Lubos, Melichar, Bohuslav

“…Background Bevacizumab and aflibercept are currently the mainstay of antiangiogenic therapy for metastatic colorectal carcinoma (mCRC). They are often used in…”
Get full text

The INSURE Study (INSIGHT MM, UVEA-IXA, REMIX): A Pooled Analysis of Relapsed/Refractory Multiple Myeloma (RRMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice by Leleu, Xavier, Boccadoro, Mario, Lee, Hans C., Zonder, Jeffrey A., Macro, Magaret, Ramasamy, Karthik, Hulin, Cyrille, Silar, Jiri, Kuhn, Matyáš, Ren, Kaili, Bent-Ennakhil, Nawal, Bouillie, Sylvie, Cherepanov, Dasha, Stull, Dawn Marie, Terpos, Evangelos

“…Background: IRd has been approved for the treatment of RRMM based on the results of the TOURMALINE-MM1 study, (median progression-free survival [PFS] with IRd…”
Get full text

Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib–lenalidomide–dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study by Lee, Hans C., Ramasamy, Karthik, Macro, Margaret, Davies, Faith E., Abonour, Rafat, Rhee, Frits, Hungria, Vania T. M., Puig, Noemi, Ren, Kaili, Silar, Jiri, Enwemadu, Victoria, Cherepanov, Dasha, Leleu, Xavier

“…Objectives To characterize the impact of prior exposure and refractoriness to lenalidomide or proteasome inhibitors (PIs) on the effectiveness and safety of…”
Get full text

Lung Cancer in Non-smokers in Czech Republic: Data from LUCAS Lung Cancer Clinical Registry by Venclicek, Ondrej, Skrickova, Jana, Brat, Kristian, Fischer, Ondrej, Havel, Libor, Hrnciarik, Michal, Marel, Miloslav, Opalka, Petr, Krakorova, Gabriela, Rozsivalova, Denisa, Kultan, Juraj, Mullerova, Andrea, Zarnayova, Lydia, Smickova, Petra, Vasakova, Martina, Gyorfy, Zsuzsanna, Jirousek, Michal, Krejci, Daniel, Krejci, Jana, Zuna, Petr, Svaton, Martin, Hrda, Kristyna, Duba, Jaroslav, Alahakoon, Jana, Svoboda, Michal, Silar, Jiri

“…Background/Aim: LUCAS is a clinical lung cancer registry (ClinicalTrials.gov identifier is NCT04228237), prospectively collecting data from newly diagnosed…”
Get full text

P-268: INSURE: a global pooled analysis of patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with ixazomib-lenalidomidedexamethasone (IRd) in routine clinical practice by Ramasamy, Karthik, Hulin, Cyrille, Leleu, Xavier, Boccadoro, Mario, Lee, Hans, Zonder, Jeffrey, Silar, Jiri, Kuhn, Matyáš, Ren, Kaili, Bent-Ennakhil, Nawal, Bouillie, Sylvie, Cherepanov, Dasha, Stull, Dawn Marie, Terpos, Evangelos, Macro, Margaret

Get full text

Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study by Hajek, Roman, Minarik, Jiri, Straub, Jan, Pour, Ludek, Jungova, Alexandra, Berdeja, Jesus G., Boccadoro, Mario, Brožová, Lucie, Spencer, Andrew, van Rhee, Frits, Vela-Ojeda, Jorge, Thompson, Michael A., Abonour, Rafat, Chari, Ajai, Cook, Gordon, Costello, Caitlin L., Davies, Faith E., Hungria, Vania T.M., Lee, Hans C., Leleu, Xavier, Puig, Noemi, Rifkin, Robert M., Terpos, Evangelos, Usmani, Saad Z., Weisel, Katja C., Zonder, Jeffrey A., Bařinová, Magda, Kuhn, Matyáš, Silar, Jiri, Capkova, Lenka, Galvez, Kenny, Lu, Jin, Skacel, Tomas, Elliott, Jennifer, Demers, Brittany, Stull, Dawn Marie, Ren, Kaili, Maisnar, Vladimir

“…Background Ixazomib, the first oral proteasome inhibitor, has been approved for >3 years in >70 countries, for the treatment of RRMM pts who have received ≥1…”
Get full text

Considering the Question of the "Accuracy" of Measurements of the Share of Agriculture in National Income by Silar, Jiri

Get full text

A Thesis Concerning the Concept of Economic Reform in the Management of Agriculture by BACA, JÁN, ŠILAR, JIRI

Get full text